**Section 4**

**Head and Neck** 

148 Otolaryngology

Vieira MN; McInnes FR & Jack MA. (1997) Comparative assessment of electroglottographic

Warren DW; Rochet AP; Dalston RM & Mayo R. (1992) Controlling changes in vocal tract

Woo P; Casper J; Colton R & Brewer D. (1994) Diagnosis and treatment of persistent

Zhang Z. (2009) Characteristics of phonation onset in a two-layer vocal fold model. *J Acoust* 

resistance. *J Acoust Soc Am*. 91(5):2947-53. ISSN 0001-4966

*Laryngoscope*. 104(9):1084-91. ISSN 1531-4995

*Soc Am*. 125(2):1091-102. ISSN 0001-4966

40(1):170-82. ISSN 1558-9192

and acoustic measures of jitter in pathological voices. *J Speech Lang Hear Res.*

dysphonia after laryngeal surgery: a retrospective analysis of 62 patients.

**9** 

*Japan* 

**Microtubule and Cdc42 are the Main Targets of** 

Many squamous cell carcinoma (SCC) of the head and neck presents with locally advanced disiease. In such cases, a combination chemotherapy of docetaxel, cisplatin, and 5FU, followed by radiation improved their survival (Posner et al. 2007; Vermorken et al. 2007). That is, addition of docetaxel to the combination of cisplatin and fluorouracil improves survival in head and neck squamous cell carcinoma. In a recent work to elucidate the possible mechanism, we investigated the effect of docetaxel on cell movement using head and neck cancer cell lines Hep2 and Ca9-22. Docetaxel treatment suppressed migration and invasiveness of head and neck cancer cells in vitro. We investigated the downstream effectors that control invasiveness after docetaxel

We used the same IC10 and IC50 concentrations (Table 1) (Kogashiwa et al. 2010) as our

Docetaxel 5 nM 23 nM

Docetaxel 6 nM 11 nM

previous study. At IC10 concentrations, anti-proliferative effect was not observed.

Cell line IC10 IC50 HEp-2 Cisplatin 2 µM 20 µM

Ca9-22 Cisplatin 10 µM 40 µM

IC10 or IC50 values after 1 hour drug exposure followed by a 96 hours incubation in two head

**1. Introduction** 

administration in the present work.

Table 1 IC10 or IC50 values in two cells

and neck cell lines.

**2. IC10 and IC50 in HEp-2 and Ca9-22 cells** 

**Docetaxel's Suppression of Invasiveness of** 

Yasunao Kogashiwa1, Hiroyuki Sakurai2 and Naoyuki Kohno1

*1Department of Otorhinolaryngology, Head and Neck Surgery,* 

**Head and Neck Cancer Cells** 

*Kyorin University School of Medicine,* 

 *Kyorin University School of Medicine,* 

*2Department of Pharmacology and Toxicology,* 
